Table 2 Characteristics of the final sample (n = 41). p value is for two-tailed independent samples t test between the two groups. 34 subjects (18 low-risk and 16 high-risk subjects) had no data points missing. The missing data are denoted and specifieda,c,d.

From: Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB1 receptor availability

 

Low-risk males (n = 22)

High-risk males (n = 19)

p value

mean

SD

mean

SD

 

Age (years)

23.0

2.9

27.1

4.3

<0.001

BMI (kg/m2)

22.0

1.9

27.2

1.9

<0.001

Body fat (%)a

16.4

5.5

29.1

7.8

<0.001

Physical exercise (hours/week)

6.2

2.8

2.7

1.0

<0.001

Family Risk score (0–4)

0.1

0.3

1.4

0.9

<0.001

Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)b

1.2

0.7

2.2

0.8

<0.001

Fasting plasma glucose (mmol/l)

4.9

0.5

5.5

0.4

<0.001

2-h plasma glucose in oral glucose tolerance test (mmol/l)

4.8

1.0

5.9

1.4

0.004

Injected activity of [11C]carfentanil (MBq)

244.5

10.7

252.6

10.7

0.02

Injected activity of [18F]FDG (MBq)c

153.7

10.3

159.4

8.9

0.08

Injected activity of [18F]FMPEP-d2 (MBq)d

188.2

11.0

187.6

14.8

0.88

  1. aBody fat percentage for high-risk subjects is computed with n = 18, since one high-risk subject didn’t complete the body composition analysis.
  2. bHOMA-IR indexes body insulin resistance and is quantified from fasting blood values with the equation: HOMA-IR = (fP-Glucose × fP-Insulin)/22.5.
  3. cMean and SD for the low-risk (n = 19) and high-risk subjects (n = 19) that completed the [18F]FDG scan successfully.
  4. dMean and SD for the low-risk (n = 20) and high-risk subjects (n = 16) that completed the [18F]FMPEP-d2 scan successfully.
Back to article page